Gyroscope Therapeutics announced today that it received a commitment from Sanofi (NYSE:SNY) to invest up to $60 million.
London-based Gyroscope will receive a $40 million investment from Sanofi initially. That $40 million represents a premium to Gyroscope’s previous Series C financing, with the remaining $20 million to be invested contingent on a future qualifying investment round and other certain closing conditions.
Get the full story at our sister site, Drug Delivery Business News.